Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412374 | 0.98 | CYP1A2 (0.67) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL5639911 | 0.91 | HDAC1 (0.61) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL3267877 | 0.89 | HDAC1 (0.63) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4411547 | 0.89 | MMP3 (0.54) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL6189108 | 0.88 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| Isophthalic Acid SCHEMBL17394551 | 0.86 | SMN1; SMN2 (0.60) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4411183 | 0.86 | KDM4E (0.58) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4412344 | 0.84 | MMP3 (0.63) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| SCHEMBL4412300 | 0.84 | MMP3 (0.50) | CYP1A2CYP3A4CYP2C19CYP2C9TSHR | |
| Hydrochloric Acid SCHEMBL5452550 | 0.81 | ALDH1A1 (0.71) | RAB9AKMT2ANPC1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586437-B2 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SEPRACOR INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | SEPRACOR, INC. | 2003-05-01 | — | — | US | disclosed |
| US-6469008-B2 | THERAPY OF PSYCHOSIS IN A HUMAN COMPRISING ADMINISTERING (R)-HYDROXYNEFAZODONE OR A PHARMACEUTICALLY ACCEPTABLE SALT | SEPRACOR INC. | 2002-10-22 | — | — | US | disclosed |
| WO-2002069951-A2 | COMPOSITION CONTAINING A NEFAZONOID SUCH AS NEFAZODONE AND A SEROTONIN-INHIBITOR SUCH AS FLUOXETINE | SEPRACOR INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| US-20020077326-A1 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SEPRACOR INC. | 2002-06-20 | — | — | US | disclosed |
| US-20020058675-A1 | (R)-hydroxynefazodone antipsychotic therapy | SEPRACOR INC. (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0568437-B1 | Antidepressant 3-Halophenylpiperazinyl-propyl Derivatives of Substituted Triazolones and Triazoldiones | BRISTOL MYERS SQUIBB CO (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-0568437-A1 | Antidepressant 3-Halophenylpiperazinyl-propyl Derivatives of Substituted Triazolones and Triazoldiones | Bristol-Myers Squibb Company (US) | 1993-11-03 | — | — | EP | disclosed |
| US-5256664-A | Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-10-26 | — | — | US | disclosed |
| US-4575555-A | ANTIDEPRESSANTS | MEAD JOHNSON & COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
| US-4487773-A | ANTISEROTONINE AGENTS | MEAD JOHNSON & COMPANY (US) | 1984-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077326-A1 | Administering (S)-hydroxynefazodone or its salt for therapy of psychosis | SLC6A3, SLC6A2, SLC6A4 | HDAC1 1029/4885HDAC2 1160/4885CYP1A2 1827/4885 |
| US-20030083338-A1 | Compositions and methods for management of serotonin-mediated disorders | HTR5A, TPH1, HTR4 | HDAC1 3504/4885HDAC2 3066/4885CYP1A2 305/4885 |
| US-20020058675-A1 | (R)-hydroxynefazodone antipsychotic therapy | GABRE, GRIN2A, HTR3E | HDAC1 1086/4885HDAC2 683/4885CYP1A2 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.